SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Norris Medicines - Quaterly Results

25 May 2022 Evaluate
The sales slipped to Rs. 8.19 millions, down -68.18% for the March 2022 quarter as against Rs. 25.74 millions during the year-ago period.The Net Loss for the quarter ended March 2022 is Rs. -22.33 millions as compared to Net Loss of Rs. -31.75 millions of corresponding quarter ended March 2021 Operating profit Margin for the quarter ended March 2022 improved to -4.15% as compared to -10.32% of corresponding quarter ended March 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 8.19 25.74 -68.18 94.38 122.51 -22.96 94.38 122.51 -22.96
Other Income 0.15 0.24 -37.50 0.26 0.50 -48.00 0.26 0.50 -48.00
PBIDT -4.15 -10.32 -59.79 -0.46 -16.91 -97.28 -0.46 -16.91 -97.28
Interest 0.82 10.47 -92.17 14.82 16.34 -9.30 14.82 16.34 -9.30
PBDT -4.97 -20.79 -76.09 -15.28 -33.25 -54.05 -15.28 -33.25 -54.05
Depreciation 6.57 1.27 417.32 6.57 6.67 -1.50 6.57 6.67 -1.50
PBT -11.54 -22.06 -47.69 -21.85 -39.92 -45.27 -21.85 -39.92 -45.27
TAX 10.79 9.69 11.35 10.79 9.69 11.35 10.79 9.69 11.35
Deferred Tax 10.79 9.69 11.35 10.79 9.69 11.35 10.79 9.69 11.35
PAT -22.33 -31.75 -29.67 -32.64 -49.61 -34.21 -32.64 -49.61 -34.21
Equity 99.26 99.26 0.00 99.26 99.26 0.00 99.26 99.26 0.00
PBIDTM(%) -50.67 -40.09 26.38 -0.49 -13.80 -96.47 -0.49 -13.80 -96.47

Norris Medicines Share Price

14.97 0.22 (1.49%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×